| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.2 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.2 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |